This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raponi, M. Articles by Beer, D. G. Search for Related Content PubMed PubMed Citation Articles by Raponi, M. Articles by Beer, D. G.

Gene Expression Signatures for Predicting Prognosis of Squamous Cell and Adenocarcinomas of the Lung

¹ Veridex, LLC, a Johnson & Johnson company, San Diego, California; Departments of ² Surgery, ³ Biostatistics, and ⁴ Pathology, and ⁵ Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan; and ⁶ Department of Pathology, University of Virginia, Charlottesville, Virginia

Requests for reprints: Mitch Raponi, Veridex LLC, a Johnson & Johnson company, Molecular Diagnostics, 3210 Merryfriend Row, San Diego, CA 92121. Phone: 858-320-3319; E-mail: mraponi1{at}vrxus.jnj.com.

Non–small-cell lung cancers (NSCLC) compose 80% of all lung carcinomas with squamous cell carcinomas (SCC) and adenocarcinoma representing the majority of these tumors. Although patients with early-stage NSCLC typically have a better outcome, 35% to 50% will relapse within 5 years after surgical treatment. We have profiled primary squamous cell lung carcinomas from 129 patients using Affymetrix U133A gene chips. Unsupervised analysis revealed two clusters of SCC that had no correlation with tumor stage but had significantly different overall patient survival (P = 0.036). The high-risk cluster was most significantly associated with down-regulation of epidermal development genes. Cox proportional hazard models identified an optimal set of 50 prognostic mRNA transcripts using a 5-fold cross-validation procedure. Quantitative reverse transcription-PCR and immunohistochemistry using tissue microarrays were used to validate individual gene candidates. This signature was tested in an independent set of 36 SCC samples and achieved 84% specificity and 41% sensitivity with an overall predictive accuracy of 68%. Kaplan-Meier analysis showed clear stratification of high-risk and low-risk patients [log-rank P = 0.04; hazard ratio (HR), 2.66; 95% confidence interval (95% CI), 1.01-7.05]. Finally, we combined the SCC classifier with our previously identified adenocarcinoma prognostic signature and showed that the combined classifier had a predictive accuracy of 71% in 72 NSCLC samples also showing significant differences in overall survival (log-rank P = 0.0002; HR, 3.54; 95% CI, 1.74-7.19). This prognostic signature could be used to identify patients with early-stage high-risk NSCLC who might benefit from adjuvant therapy following surgery. (Cancer Res 2006; 66(15): 7466-72)

This article has been cited by other articles:

				D. S. Hsu, C. R. Acharya, B. S. Balakumaran, R. F. Riedel, M. K. Kim, M. Stevenson, S. Tuchman, S. Mukherjee, W. Barry, H. K. Dressman, et al. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer PNAS, March 31, 2009; 106(13): 5312 - 5317. [Abstract] [Full Text] [PDF]

				P. C. Boutros, S. K. Lau, M. Pintilie, N. Liu, F. A. Shepherd, S. D. Der, M.-S. Tsao, L. Z. Penn, and I. Jurisica Prognostic gene signatures for non-small-cell lung cancer PNAS, February 24, 2009; 106(8): 2824 - 2828. [Abstract] [Full Text] [PDF]

				P. Broet, S. Camilleri-Broet, S. Zhang, M. Alifano, D. Bangarusamy, M. Battistella, Y. Wu, M. Tuefferd, J.-F. Regnard, E. Lim, et al. Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection Cancer Res., February 1, 2009; 69(3): 1055 - 1062. [Abstract] [Full Text] [PDF]

				E. Bulk, B. Sargin, U. Krug, A. Hascher, Y. Jun, M. Knop, C. Kerkhoff, V. Gerke, R. Liersch, R. M. Mesters, et al. S100A2 Induces Metastasis in Non-Small Cell Lung Cancer Clin. Cancer Res., January 1, 2009; 15(1): 22 - 29. [Abstract] [Full Text] [PDF]

				P. Roepman, J. Jassem, E. F. Smit, T. Muley, J. Niklinski, T. van de Velde, A. T. Witteveen, W. Rzyman, A. Floore, S. Burgers, et al. An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non-Small-Cell Lung Cancer Clin. Cancer Res., January 1, 2009; 15(1): 284 - 290. [Abstract] [Full Text] [PDF]

				N. L. Guo, Y.-W. Wan, K. Tosun, H. Lin, Z. Msiska, D. C. Flynn, S. C. Remick, V. Vallyathan, A. Dowlati, X. Shi, et al. Confirmation of Gene Expression-Based Prediction of Survival in Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2008; 14(24): 8213 - 8220. [Abstract] [Full Text] [PDF]

				E.-S. Lee, D.-S. Son, S.-H. Kim, J. Lee, J. Jo, J. Han, H. Kim, H. J. Lee, H. Y. Choi, Y. Jung, et al. Prediction of Recurrence-Free Survival in Postoperative Non-Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression Clin. Cancer Res., November 15, 2008; 14(22): 7397 - 7404. [Abstract] [Full Text] [PDF]

				D. J. Raz, M. R. Ray, J. Y. Kim, B. He, M. Taron, M. Skrzypski, M. Segal, D. R. Gandara, R. Rosell, and D. M. Jablons A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma Clin. Cancer Res., September 1, 2008; 14(17): 5565 - 5570. [Abstract] [Full Text] [PDF]

				M. Skrzypski, E. Jassem, M. Taron, J. J. Sanchez, P. Mendez, W. Rzyman, G. Gulida, D. Raz, D. Jablons, M. Provencio, et al. Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung Clin. Cancer Res., August 1, 2008; 14(15): 4794 - 4799. [Abstract] [Full Text] [PDF]

				E. Bulk, A. Hascher, R. Liersch, R. M. Mesters, S. Diederichs, B. Sargin, V. Gerke, M. Hotfilder, J. Vormoor, W. E. Berdel, et al. Adjuvant Therapy with Small Hairpin RNA Interference Prevents Non-Small Cell Lung Cancer Metastasis Development in Mice Cancer Res., March 15, 2008; 68(6): 1896 - 1904. [Abstract] [Full Text] [PDF]

				E. C. Finger, R. S. Turley, M. Dong, T. How, T. A. Fields, and G. C. Blobe T{beta}RIII suppresses non-small cell lung cancer invasiveness and tumorigenicity Carcinogenesis, March 1, 2008; 29(3): 528 - 535. [Abstract] [Full Text] [PDF]

				Z. Sun, D. A. Wigle, and P. Yang Non-Overlapping and Non-Cell-Type-Specific Gene Expression Signatures Predict Lung Cancer Survival J. Clin. Oncol., February 20, 2008; 26(6): 877 - 883. [Abstract] [Full Text] [PDF]

				S. K. Lau, P. C. Boutros, M. Pintilie, F. H. Blackhall, C.-Q. Zhu, D. Strumpf, M. R. Johnston, G. Darling, S. Keshavjee, T. K. Waddell, et al. Three-Gene Prognostic Classifier for Early-Stage Non Small-Cell Lung Cancer J. Clin. Oncol., December 10, 2007; 25(35): 5562 - 5569. [Abstract] [Full Text] [PDF]

				S. M. Janes and F. McCaughan Where next for lung cancer gene expression profiling? Eur. Respir. J., July 1, 2007; 30(1): 5 - 6. [Full Text] [PDF]

				J. E. Larsen, S. J. Pavey, R. Bowman, I. A. Yang, B. E. Clarke, M. L. Colosimo, N. K. Hayward, and K. M. Fong Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement Eur. Respir. J., July 1, 2007; 30(1): 21 - 26. [Abstract] [Full Text] [PDF]

				J. E. Larsen, S. J. Pavey, L. H. Passmore, R. V. Bowman, N. K. Hayward, and K. M. Fong Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma Clin. Cancer Res., May 15, 2007; 13(10): 2946 - 2954. [Abstract] [Full Text] [PDF]

				J. E. Larsen, S. J. Pavey, L. H. Passmore, R. Bowman, B. E. Clarke, N. K. Hayward, and K. M. Fong Expression profiling defines a recurrence signature in lung squamous cell carcinoma Carcinogenesis, March 1, 2007; 28(3): 760 - 766. [Abstract] [Full Text] [PDF]

				R. S. Herbst and S. M. Lippman Molecular Signatures of Lung Cancer -- Toward Personalized Therapy N. Engl. J. Med., January 4, 2007; 356(1): 76 - 78. [Full Text] [PDF]